SG11201909018VA - Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide - Google Patents
Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamideInfo
- Publication number
- SG11201909018VA SG11201909018VA SG11201909018VA SG11201909018VA SG 11201909018V A SG11201909018V A SG 11201909018VA SG 11201909018V A SG11201909018V A SG 11201909018VA SG 11201909018V A SG11201909018V A SG 11201909018VA
- Authority
- SG
- Singapore
- Prior art keywords
- methyl
- international
- princeton
- route
- new jersey
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/62—Preparation of compounds containing amino groups bound to a carbon skeleton by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/03—Monoamines
- C07C211/04—Mono-, di- or tri-methylamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/09—Diamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/08—Preparation of carboxylic acid amides from amides by reaction at nitrogen atoms of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/90—Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
- C07C303/28—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) W I PO I PCT 0111111010 0111 °nolo OH mil oo1 moi IIII iflo oimIE (10) International Publication Number WO 2018/183656 Al (51) International Patent Classification: C07D 403/12 (2006.01) A61P 29/00 (2006.01) A61K 31/501 (2006.01) (21) International Application Number: PCT/US2018/025114 (22) International Filing Date: 29 March 2018 (29.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/478,789 30 March 2017 (30.03.2017) US (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY [US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). (72) Inventors: ZHANG, Yanlei; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). GALELLA, Michael A.; c/o Bris- tol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). (74) Agent: GREENBLATT, Gary D. et al.; Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) (54) Title: CRYSTAL FORM OF 6-(CYCLOPROPANECARBOXAMIDO)-44(2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIA- ZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE FIG. 1 00 \" (57) : Disclosed is crystalline Form A of 6-(cyclopropanecarboxamido)-44(2-methoxy-3-(1-methyl-1H-1,2,4-tria- zol-3-yl)phenyl) amino)-N-(methyl-d3)pyridazine-3-carboxamide. Form A is a neat crystalline form. Characterization data for Form 0 A are disclosed.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762478789P | 2017-03-30 | 2017-03-30 | |
| PCT/US2018/025114 WO2018183656A1 (en) | 2017-03-30 | 2018-03-29 | Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909018VA true SG11201909018VA (en) | 2019-10-30 |
Family
ID=62002470
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909018V SG11201909018VA (en) | 2017-03-30 | 2018-03-29 | Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide |
| SG11201908947Q SG11201908947QA (en) | 2017-03-30 | 2018-03-29 | Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908947Q SG11201908947QA (en) | 2017-03-30 | 2018-03-29 | Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US10899745B2 (en) |
| EP (4) | EP3601270A1 (en) |
| JP (5) | JP7260481B2 (en) |
| KR (4) | KR102857398B1 (en) |
| CN (4) | CN110914260A (en) |
| AU (3) | AU2018244451B2 (en) |
| CA (2) | CA3058209A1 (en) |
| CY (1) | CY1124194T1 (en) |
| DK (1) | DK3601268T3 (en) |
| EA (2) | EA201992300A1 (en) |
| ES (2) | ES2864450T3 (en) |
| HR (1) | HRP20210764T1 (en) |
| HU (1) | HUE054886T2 (en) |
| IL (3) | IL269594B2 (en) |
| LT (1) | LT3601268T (en) |
| MX (4) | MX392693B (en) |
| PL (1) | PL3601268T3 (en) |
| PT (1) | PT3601268T (en) |
| RS (1) | RS61816B1 (en) |
| SG (2) | SG11201909018VA (en) |
| SI (1) | SI3601268T1 (en) |
| SM (1) | SMT202100239T1 (en) |
| WO (2) | WO2018183656A1 (en) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20150944A1 (en) | 2012-11-08 | 2015-06-20 | Bristol Myers Squibb Co | USEFUL AMIDE SUBSTITUTED HETEROCYCLIC COMPOUNDS AS MODULATORS OF INTERLEUKIN 12 (IL-12), INTERLEUKIN 23 (IL-23) AND / OR INTERFERON ALPHA (IFN (alpha)) RESPONSES |
| HRP20210764T1 (en) * | 2017-03-30 | 2021-07-09 | Bristol-Myers Squibb Company | PROCEDURE FOR PREPARATION 6- (CYCLOPROPANAMIDO) -4 - ((2-METHOXY-3- (1-METHYL-1H-1,2,4-TRIAZOL-3-YL) PHENYL) AMINO) -N- (METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE |
| CN118994117A (en) | 2018-05-31 | 2024-11-22 | 百时美施贵宝公司 | Crystalline forms of a compound |
| KR20210119426A (en) * | 2019-01-28 | 2021-10-05 | 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 | Pyridazine derivative inhibitors, and methods for their preparation and uses |
| CN111484480B (en) * | 2019-01-29 | 2023-08-11 | 上海翰森生物医药科技有限公司 | A polycyclic derivative inhibitor, its preparation method and application |
| KR20220020890A (en) * | 2019-06-12 | 2022-02-21 | 브리스톨-마이어스 스큅 컴퍼니 | 6-(Cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-( methyl-D3) crystalline salt form of pyridazine-3-carboxamide |
| AU2020349524A1 (en) | 2019-09-18 | 2022-03-31 | Bristol-Myers Squibb Company | Dosage forms for Tyk2 inhibitors |
| CN114787152A (en) * | 2019-12-27 | 2022-07-22 | 苏州科睿思制药有限公司 | BMS-986165 crystal form, and preparation method and application thereof |
| CN114787154A (en) * | 2020-01-19 | 2022-07-22 | 苏州科睿思制药有限公司 | Crystal form of Deucravicitinib, preparation method and application thereof |
| WO2021143430A1 (en) * | 2020-01-19 | 2021-07-22 | 苏州科睿思制药有限公司 | Bms-986165 hydrochloride crystal form, preparation method therefor and use thereof |
| US20230159520A1 (en) * | 2020-02-26 | 2023-05-25 | Beigene, Ltd. | Tyk-2 inhibitor |
| CN113735836B (en) * | 2020-05-28 | 2023-05-30 | 江苏先声药业有限公司 | Pyridazine compound and application thereof |
| CN113773262B (en) * | 2020-06-09 | 2024-08-09 | 江苏先声药业有限公司 | Pyridazines compounds |
| CA3183368A1 (en) | 2020-06-22 | 2021-12-30 | Qiuwen WANG | Tyk-2 inhibitor |
| JP2023534492A (en) * | 2020-07-24 | 2023-08-09 | 上▲海▼翰森生物医▲薬▼科技有限公司 | Crystal Forms of Pyridazine Derivatives Free Base, and Methods for Their Preparation and Uses |
| WO2022021684A1 (en) * | 2020-07-31 | 2022-02-03 | 苏州科睿思制药有限公司 | Crystalline form csv of bms-986165 hydrochloride, preparation method therefor, and uses thereof |
| BR112023004824A2 (en) | 2020-09-18 | 2023-04-18 | Bristol Myers Squibb Co | DOSAGE FORMS FOR TYK2 INHIBITORS COMPRISING STUMBLE CORE |
| CN116615200B (en) * | 2020-10-20 | 2025-04-29 | 杭州领业医药科技有限公司 | Crystalline forms of pyridazine derivatives |
| AU2022214313A1 (en) | 2021-01-29 | 2023-08-17 | Bristol-Myers Squibb Company | Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
| US20240190845A1 (en) | 2021-03-29 | 2024-06-13 | Bristol-Myers Squibb Company | Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
| AU2022271794A1 (en) | 2021-05-14 | 2024-01-04 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| KR20240050380A (en) | 2021-08-20 | 2024-04-18 | 브리스톨-마이어스 스큅 컴퍼니 | 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-( Crystal form of methyl-D3)pyridazine-3-carboxamide |
| AU2022350509A1 (en) * | 2021-09-23 | 2024-04-04 | Bristol-Myers Squibb Company | Methods of treating hair-loss disorders with tyk2 inhibitors |
| EP4422690A1 (en) | 2021-10-28 | 2024-09-04 | Bristol-Myers Squibb Company | Topical formulations of deucravacitinib |
| WO2023102085A1 (en) | 2021-12-01 | 2023-06-08 | Teva Czech Industries S.R.O. | Solid state forms of deucravacitinib, deucravacitinib hcl and process for preparation of deucravacitinib and intermediates |
| US12222104B2 (en) * | 2022-03-21 | 2025-02-11 | General Electric Company | Turbine engine combustor and combustor liner |
| WO2023181075A1 (en) * | 2022-03-24 | 2023-09-28 | Dr. Reddy's Laboratories Limited | Amorphous solid dispersions of deucravacitinib and processes for the preparation thereof |
| CN114989103B (en) * | 2022-06-09 | 2024-07-09 | 杭州科巢生物科技有限公司 | A preparation method of 2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)aniline |
| CN117447411B (en) * | 2022-07-18 | 2025-12-23 | 苏州鹏旭医药科技有限公司 | A method for synthesizing a heterocyclic drug intermediate |
| WO2024017150A1 (en) * | 2022-07-18 | 2024-01-25 | 苏州鹏旭医药科技有限公司 | Method for synthesizing deucravacitinib |
| CN120187715A (en) * | 2022-10-28 | 2025-06-20 | 浙江华海药业股份有限公司 | A pyridazinamide compound, a pharmaceutical composition thereof and use thereof as a TYK2 inhibitor |
| WO2024236491A1 (en) * | 2023-05-15 | 2024-11-21 | Glenmark Life Sciences Limited | Process for the preparation of deucravacitinib, and crystalline forms thereof |
| EP4538259A1 (en) | 2023-10-09 | 2025-04-16 | Farmhispania Group, S.L. | Processes for the preparation of deucravacitinib |
| WO2025131031A1 (en) * | 2023-12-22 | 2025-06-26 | 上海奥博生物医药股份有限公司 | Tyk2 inhibitor and preparation method for intermediates thereof |
| WO2025186427A1 (en) | 2024-03-08 | 2025-09-12 | Curia Spain, S.A.U. | Process for the preparation of deucravacitinib and intermediates thereof and method for purifying deucravacitinib |
| WO2025259267A1 (en) | 2024-06-11 | 2025-12-18 | Vector Vitale Ip Llc | Pharmaceutical compositions for modulating inflammation and oxidative stress comprising chemically enriched elements |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6023649B2 (en) * | 1976-09-08 | 1985-06-08 | 東ソー株式会社 | Method for producing methyl bromide using hydrobromic acid |
| JPS5455501A (en) * | 1977-10-05 | 1979-05-02 | Toyo Soda Mfg Co Ltd | Continuous preparation of methyl bromide |
| US4254061A (en) * | 1979-09-11 | 1981-03-03 | E. I. Du Pont De Nemours And Company | Preparation of monomethylamine |
| US6797706B1 (en) * | 1999-06-09 | 2004-09-28 | Yamanouchi Pharmaceutical Co., Ltd. | Heterocyclecarboxamide derivative |
| CN100579579C (en) | 2002-10-01 | 2010-01-13 | 诺华疫苗和诊断公司 | Anti-cancer and anti-infectious disease compositions and methods of use thereof |
| WO2005065683A1 (en) | 2003-12-22 | 2005-07-21 | Eli Lilly And Company | Triazole, oxadiazole and thiadiazole derivative as ppar modulators for the treatment of diabetes |
| BRPI0616472A2 (en) * | 2005-09-29 | 2012-12-25 | Basf Se | molded body and processes for producing a molded body and for the continuous preparation of methylamines |
| JP5491199B2 (en) | 2007-01-19 | 2014-05-14 | アルデア バイオサイエンシズ，インコーポレイティド | MEK inhibitor |
| BR112012006956A2 (en) * | 2009-10-12 | 2015-09-15 | Bayer Cropscience Ag | 1- (pyrida-3-yl) pyrazolol and 1- (pyrimide-5-yl) pyrazolol as pesticides |
| CN103002742B (en) * | 2010-03-05 | 2016-07-13 | 卡尔约药物治疗公司 | Nuclear translocation regulator and application thereof |
| EP2548859B1 (en) * | 2010-03-18 | 2015-03-04 | Suzhou Zelgen Biopharmaceutical Co., Ltd. | Preparation methods of methyl-d3-amine and salts thereof |
| WO2013047813A1 (en) * | 2011-09-30 | 2013-04-04 | 大鵬薬品工業株式会社 | 1,2,4-triazine-6-carboxamide derivative |
| CN104125947A (en) * | 2011-12-21 | 2014-10-29 | 生物区欧洲有限公司 | Heterocyclic urea compounds |
| CN104159891B (en) * | 2012-01-10 | 2016-09-07 | 霍夫曼-拉罗奇有限公司 | Pyridazine amide compound and they are as the purposes of SYK inhibitor |
| WO2013171643A1 (en) | 2012-05-14 | 2013-11-21 | Piramal Enterprises Limited | An improved process for preparation of irbesartan |
| PE20150944A1 (en) * | 2012-11-08 | 2015-06-20 | Bristol Myers Squibb Co | USEFUL AMIDE SUBSTITUTED HETEROCYCLIC COMPOUNDS AS MODULATORS OF INTERLEUKIN 12 (IL-12), INTERLEUKIN 23 (IL-23) AND / OR INTERFERON ALPHA (IFN (alpha)) RESPONSES |
| AR094537A1 (en) | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | PIRIDIL COMPOUNDS REPLACED WITH USEFUL ALQUILAMIDE AS MODULATORS OF THE ANSWERS OF IL-12, IL-23 AND / OR IFNa |
| HRP20210764T1 (en) * | 2017-03-30 | 2021-07-09 | Bristol-Myers Squibb Company | PROCEDURE FOR PREPARATION 6- (CYCLOPROPANAMIDO) -4 - ((2-METHOXY-3- (1-METHYL-1H-1,2,4-TRIAZOL-3-YL) PHENYL) AMINO) -N- (METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE |
| CN118994117A (en) * | 2018-05-31 | 2024-11-22 | 百时美施贵宝公司 | Crystalline forms of a compound |
-
2018
- 2018-03-29 HR HRP20210764TT patent/HRP20210764T1/en unknown
- 2018-03-29 JP JP2019553556A patent/JP7260481B2/en active Active
- 2018-03-29 US US16/498,442 patent/US10899745B2/en active Active
- 2018-03-29 SG SG11201909018V patent/SG11201909018VA/en unknown
- 2018-03-29 HU HUE18718340A patent/HUE054886T2/en unknown
- 2018-03-29 PT PT187183405T patent/PT3601268T/en unknown
- 2018-03-29 EA EA201992300A patent/EA201992300A1/en unknown
- 2018-03-29 EP EP18718991.5A patent/EP3601270A1/en active Pending
- 2018-03-29 SI SI201830252T patent/SI3601268T1/en unknown
- 2018-03-29 AU AU2018244451A patent/AU2018244451B2/en active Active
- 2018-03-29 IL IL269594A patent/IL269594B2/en unknown
- 2018-03-29 LT LTEP18718340.5T patent/LT3601268T/en unknown
- 2018-03-29 AU AU2018244916A patent/AU2018244916B2/en active Active
- 2018-03-29 IL IL269586A patent/IL269586B/en unknown
- 2018-03-29 SM SM20210239T patent/SMT202100239T1/en unknown
- 2018-03-29 ES ES18718340T patent/ES2864450T3/en active Active
- 2018-03-29 ES ES21155321T patent/ES2970229T3/en active Active
- 2018-03-29 KR KR1020247034512A patent/KR102857398B1/en active Active
- 2018-03-29 KR KR1020197031635A patent/KR102642407B1/en active Active
- 2018-03-29 RS RS20210559A patent/RS61816B1/en unknown
- 2018-03-29 EP EP21155321.9A patent/EP3882237B1/en active Active
- 2018-03-29 MX MX2019011092A patent/MX392693B/en unknown
- 2018-03-29 IL IL305615A patent/IL305615A/en unknown
- 2018-03-29 JP JP2019553452A patent/JP7113023B2/en active Active
- 2018-03-29 PL PL18718340T patent/PL3601268T3/en unknown
- 2018-03-29 CN CN201880022423.XA patent/CN110914260A/en active Pending
- 2018-03-29 CN CN202310552731.6A patent/CN116813561A/en active Pending
- 2018-03-29 WO PCT/US2018/025114 patent/WO2018183656A1/en not_active Ceased
- 2018-03-29 CA CA3058209A patent/CA3058209A1/en active Pending
- 2018-03-29 EA EA201992308A patent/EA201992308A1/en unknown
- 2018-03-29 SG SG11201908947Q patent/SG11201908947QA/en unknown
- 2018-03-29 DK DK18718340.5T patent/DK3601268T3/en active
- 2018-03-29 KR KR1020257017189A patent/KR20250080914A/en active Pending
- 2018-03-29 CN CN202310263681.XA patent/CN116354939A/en active Pending
- 2018-03-29 CN CN201880021649.8A patent/CN110475774B/en active Active
- 2018-03-29 CA CA3058177A patent/CA3058177A1/en active Pending
- 2018-03-29 KR KR1020197031634A patent/KR102720054B1/en active Active
- 2018-03-29 US US15/767,388 patent/US20200239449A1/en not_active Abandoned
- 2018-03-29 WO PCT/US2018/025100 patent/WO2018183649A1/en not_active Ceased
- 2018-03-29 MX MX2019011231A patent/MX2019011231A/en unknown
- 2018-03-29 EP EP23209227.0A patent/EP4296258A3/en active Pending
- 2018-03-29 EP EP18718340.5A patent/EP3601268B1/en active Active
-
2019
- 2019-09-20 MX MX2022010495A patent/MX2022010495A/en unknown
- 2019-09-20 MX MX2022010496A patent/MX2022010496A/en unknown
-
2020
- 2020-12-22 US US17/131,718 patent/US11649226B2/en active Active
-
2021
- 2021-04-29 CY CY20211100374T patent/CY1124194T1/en unknown
- 2021-08-11 US US17/400,100 patent/US20210371404A1/en active Pending
- 2021-11-01 AU AU2021261839A patent/AU2021261839B2/en active Active
-
2022
- 2022-07-25 JP JP2022117894A patent/JP7457758B2/en active Active
-
2023
- 2023-01-27 JP JP2023010810A patent/JP7476370B2/en active Active
- 2023-04-13 US US18/134,564 patent/US20230271946A1/en active Pending
- 2023-12-11 JP JP2023208420A patent/JP2024037836A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909018VA (en) | Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide | |
| SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
| SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201907209QA (en) | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201810177VA (en) | Pet-imaging immunomodulators | |
| SG11201903359RA (en) | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma | |
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201808878UA (en) | Heterocyclic compounds as ret kinase inhibitors | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
| SG11201808163WA (en) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists | |
| SG11201810837QA (en) | Biarylmethyl heterocycles | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201809172WA (en) | Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201807549TA (en) | Combination of a cxcr4 antagonist and an immune checkpoint inhibitor | |
| SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch |